oncolyt
virus
ov
engin
andor
evolv
propag
select
cancer
tissu
dual
mechan
action
direct
kill
infect
cancer
cell
crossprim
anticanc
immun
boost
kill
uninfect
cancer
cell
goal
field
develop
ov
easili
manufactur
effici
deliv
dissemin
site
cancer
growth
undergo
rapid
intratumor
spread
select
kill
tumor
cell
caus
collater
damag
pose
risk
transmiss
popul
discuss
mani
viru
engin
strategi
pursu
optim
deliveri
intratumor
spread
safeti
ov
deriv
differ
viru
famili
continu
progress
ov
potenti
transform
paradigm
cancer
care
oncolyt
virus
ov
evolv
engin
cancer
specif
gain
momentum
new
drug
class
fight
cancer
besid
caus
death
virusinfect
cancer
cell
spread
intratumor
infect
also
boost
anticanc
immun
respons
lead
immun
destruct
uninfect
cancer
cell
paradigm
ov
review
extens
key
desir
characterist
ov
specif
potenc
safeti
specif
target
cancer
potenc
kill
infect
cell
crossprim
antitumor
immun
safeti
avoid
advers
reaction
pathogen
revers
well
establish
sever
rodent
cancer
model
singl
dose
effect
ov
complet
cure
diseas
shown
dna
rna
virus
divers
tumor
model
howev
singl
shot
cure
excit
prospect
cancer
therapi
date
clinic
outcom
typic
fallen
short
repeat
viru
administr
proven
reliabl
approach
number
anecdot
case
report
give
credenc
idea
singl
shot
ov
cure
may
achiev
clinic
practic
suggest
ov
potenti
transform
practic
oncolog
light
recent
clinic
progress
interest
approach
burgeon
one
critic
mileston
market
approv
grant
europ
usa
talimogen
laherparepvec
tvec
engin
hsv
encod
gmcsf
viru
administ
intratumor
everi
week
malign
melanoma
led
complet
resolut
inject
tumor
boost
system
antitumor
immun
lead
resolut
distant
un
infect
viscer
tumor
subsequ
clinic
studi
shown
respons
frequent
durabl
tvec
ov
coxsackieviru
combin
immun
checkpoint
reprint
order
pleas
contact
reprint
futuremedicinecom
review
maroun
ammayappan
schulz
peng
russel
futur
scienc
group
inhibitor
antibodi
therapi
anoth
signific
mileston
demonstr
system
administ
oncolyt
measl
viru
target
destroy
dissemin
cancer
human
subject
base
clinic
advanc
develop
ov
rapidli
acceler
purpos
review
discuss
viru
engin
approach
ov
perform
optim
strategi
pursu
field
point
challeng
remain
believ
perspect
particularli
valuabl
virologist
enter
field
apolog
numer
investig
whose
work
acknowledg
well
awar
omiss
due
space
constraint
approach
choos
illustr
exampl
demonstr
key
principl
review
divid
five
main
section
introduct
virus
viru
engin
ii
deliveri
iii
spread
iv
arm
v
safeti
five
topic
highli
interdepend
natur
virus
continu
evolv
adapt
occupi
almost
everi
imagin
biolog
nich
virus
infect
bacteri
archaea
protist
fungal
plant
anim
cell
genom
compos
dna
rna
may
singl
doubl
strand
posit
neg
sens
rang
size
kb
complex
gene
capac
foreign
genet
materi
hundr
base
sever
kilobas
particl
virus
differ
famili
also
vari
enorm
size
structur
rang
nm
icosahedr
helic
symmetri
without
lipid
envelop
integu
matrix
variabl
suscept
physic
disrupt
natur
occur
virus
also
offer
vast
divers
viru
life
cycl
cell
entri
replic
mechan
cell
speci
tropism
cycl
time
burst
size
innat
immun
evas
apoptosi
antivir
state
prevent
immun
combat
strategi
mode
transmiss
pathogen
mechan
divers
virus
investig
oncolyt
platform
differ
strategi
use
improv
efficaci
continu
expand
tabl
asid
differ
virus
share
fundament
similar
includ
depend
host
cell
provid
suitabl
environ
genom
amplif
gene
express
progeni
viru
product
adapt
specif
set
host
cell
condit
factor
propag
preclud
cell
fail
provid
necessari
environ
characterist
allow
virus
target
cancer
cell
selfrepl
antineoplast
therapi
might
expect
propon
given
ov
typic
abl
advanc
strong
argument
support
choic
platform
emphas
uniqu
featur
replic
kinet
genom
plastic
target
seropreval
stabil
may
lead
superior
oncolysi
howev
earli
determin
uniqu
viral
characterist
critic
driver
clinic
success
given
cancer
type
revers
genet
system
avail
virtual
viru
famili
rule
engag
new
viru
creation
well
establish
gener
effect
strategi
combin
ration
design
evolut
allow
engin
viru
mutat
fulli
adapt
intend
target
cell
rescu
biosafeti
oversight
place
academ
center
respons
engag
viru
engin
activ
rel
straightforward
matter
gener
test
new
viru
configur
use
amount
world
best
lego
set
viral
gene
noncod
sequenc
modifi
varieti
way
add
elimin
function
nonvir
gene
noncod
regulatori
element
whether
synthet
natur
occur
ad
viral
genom
confer
addit
desir
properti
overarch
engin
goal
oncolyt
virotherapi
field
gener
virus
effici
deliv
dissemin
tumor
bodi
spread
select
kill
infect
uninfect
tumor
cell
without
caus
collater
damag
pose
risk
transmiss
popul
viral
infect
well
understood
ov
applic
must
view
drug
obey
pharmacolog
principl
drug
typic
administ
patient
extrem
control
way
produc
reliabl
consist
predict
pharmacokinet
profil
absorpt
biodistribut
metabol
excret
bioavail
natur
viral
infect
obey
rule
sinc
inoculum
variabl
size
host
resist
vari
person
person
kinet
adapt
immun
respons
differ
greatli
individu
thu
outcom
natur
infect
given
pathogen
viru
rang
asymptomat
seroconvers
full
blown
diseas
primari
viru
inoculum
must
contain
suffici
viru
particl
overcom
initi
host
defens
site
entri
virus
enter
mucou
membran
gi
respiratori
tract
other
enter
via
direct
inocul
blood
stream
follow
needl
stick
arthropod
blood
meal
ov
deliv
way
tradit
drug
introduc
highli
concentr
viru
inoculum
bodi
via
oral
intraven
iv
intranas
transderm
subcutan
intramuscular
rout
whereupon
dispers
inocul
viru
progeni
take
target
cancer
tissu
major
factor
distinguish
ov
tradit
drug
selfamplifi
spread
deliveri
peak
concentr
may
reach
sometim
treatment
administ
biolog
amplif
viral
replic
import
differ
viral
therapi
tradit
drug
concentr
drug
diminish
time
well
describ
rate
depend
clearanc
elimin
bodi
cours
viral
infect
viral
load
initi
small
increas
final
decreas
rather
follow
specif
rate
law
elimin
limit
amount
viru
particl
replic
site
inocul
input
progeni
virus
either
drain
lymphat
fluid
nearest
lymph
node
go
directli
circul
spread
local
spread
system
eventu
arriv
specif
target
organ
patholog
induc
high
level
viral
replic
target
organ
directli
kill
infect
cell
recruit
immun
system
kill
time
provok
local
inflammatori
respons
ov
therapi
begin
administr
viru
patient
drug
sever
approach
taken
optim
oncolyt
virotherapi
indic
maxim
deliveri
tumor
cell
infect
profound
impact
degre
viru
must
propag
infect
cell
cur
therapi
higher
number
random
dispers
infecti
center
establish
tumor
deliveri
viru
effect
viru
although
paramet
must
optim
viru
model
iv
administr
ov
common
deliveri
method
introduc
larg
amount
viru
one
compart
short
time
rapid
deliveri
massiv
viru
inoculum
parallel
typic
occur
natur
infect
potenti
allow
spread
ov
infect
outpac
host
defens
success
deliveri
context
ov
infect
requir
critic
viral
concentr
achiev
within
tumor
allow
suffici
oncolysi
system
spread
viru
site
diseas
safe
reproduc
pattern
iv
deliveri
iv
deliveri
ov
seem
advantag
set
metastat
diseas
allow
viru
potenti
access
site
diseas
via
circul
soon
infus
clinic
set
system
deliveri
may
prefer
sinc
broadli
applic
inocul
regardless
tumor
locat
total
tumor
burden
yet
attempt
system
deliveri
shown
limit
success
administ
viru
immedi
dilut
circul
blood
volum
l
extrem
high
dose
need
achiev
meaning
circul
titer
clinic
trial
use
oncolyt
pox
viru
demonstr
viru
could
detect
tumor
patient
receiv
least
pfu
per
iv
dose
without
viru
detect
tumor
lower
dose
cohort
patient
import
dilut
effect
dose
requir
iv
therapi
may
higher
administr
result
signific
manufactur
challeng
well
uniqu
set
toxic
administr
high
titer
viru
intraven
lead
hepatotox
thrombocytopenia
lymphopenia
follow
path
ov
iv
line
tumor
quickli
illustr
challeng
iv
deliveri
first
viru
rapidli
dilut
circul
infect
neutral
serum
protein
includ
antibodi
complement
larg
proport
sequest
reticuloendotheli
phagocyt
spleen
liver
viru
particl
reach
tumor
vasculatur
without
first
neutral
must
extravas
fenestr
pore
vascular
endotheli
cell
tumor
capillari
interstiti
space
tumor
must
negoti
extracellular
matrix
ecm
reach
infect
resid
cancer
cell
tumor
vasculatur
aid
limit
viral
access
tumor
typic
unorgan
growth
pattern
produc
vasculatur
tumultu
insuffici
result
heterogen
perfus
throughout
parenchyma
decreas
perfus
limit
format
infecti
center
evenli
throughout
tumor
manipul
physiolog
paramet
blood
pressur
system
vascular
resist
preferenti
increas
tumor
perfus
promot
better
deliveri
viral
vector
tumor
vessel
viru
must
move
intravascular
compart
interstitium
cross
vascular
endothelium
continu
journey
interstiti
space
final
reach
permiss
tumor
cell
least
theori
virus
cross
endotheli
line
tumor
neovessel
diffus
activ
infect
traffick
insid
surfac
marrowderiv
cell
capabl
diapedesi
tumor
gener
poor
lymphat
drainag
leaki
blood
vessel
wide
rang
pore
size
help
explain
phenomenon
enhanc
permeabl
retent
nanoparticl
ov
tumor
parenchyma
tumor
pore
fenestr
tumor
capillari
may
larg
enough
permit
passiv
diffus
virus
depend
size
mani
tumor
review
maroun
ammayappan
schulz
peng
russel
futur
scienc
group
endothelium
suffici
organ
type
extravas
simpli
possibl
clearli
abil
infect
activ
endotheli
cell
tumor
neovessel
would
attract
target
properti
ov
enhanc
entri
tumor
parenchyma
releas
viral
progeni
ablumen
side
blood
vessel
intravascular
coagul
capillari
could
also
provok
virusinfect
endotheli
cell
react
clot
inflammatori
factor
viru
engin
strategi
pursu
achiev
goal
exampl
display
polypeptid
ligand
echistatin
urokinas
plasminogen
activ
surfac
measl
viru
target
integrin
upar
endotheli
cell
surfac
receptor
respect
also
least
one
ov
vesicular
stomat
viru
vsv
shown
natur
capabl
infect
neovessel
endothelium
implant
mous
tumor
studi
highlight
potenti
toxic
approach
name
intravascular
coagul
requir
heparin
therapi
prevent
anoth
approach
help
ov
extravas
tempor
creat
pore
throughout
tumor
microvasculatur
enhanc
transport
viru
tumor
interstitium
done
applic
focus
ultrasound
presenc
contrast
agent
polym
microbubbl
polym
inject
intraven
freeli
circul
without
harm
tissu
expos
ultrasound
wave
oscil
induc
pore
format
cavit
surround
tissu
ultrasound
focus
tumor
infus
viru
increas
viral
extravas
shown
enhanc
vaccinia
viru
deliveri
tumor
xenograft
increas
viral
transgen
express
tumor
mani
strategi
develop
enhanc
ov
iv
deliveri
deliveri
administr
directli
deliv
high
concentr
ov
parenchyma
inject
tumor
may
result
spread
viru
distant
site
metastasi
tvec
administ
inject
access
skin
tumor
patient
metastat
malign
melanoma
inject
repeat
everi
week
lesion
resolv
fail
respond
interestingli
viremia
document
patient
suggest
regress
noninject
lesion
like
immunemedi
due
direct
oncolysi
immedi
follow
deliveri
small
level
viru
detect
blood
leakag
injur
tumor
vasculatur
small
amount
viru
quickli
clear
system
also
viru
inject
tumor
frequent
extrud
immedi
inject
track
syring
remov
especi
smaller
higher
pressur
tumor
howev
system
viral
spread
occur
follow
administr
initi
expos
tumor
cell
capabl
amplifi
input
viru
releas
progeni
bloodstream
secondari
viremia
may
peak
sever
day
viru
deliveri
current
use
ov
often
detect
secondari
viremia
occur
close
mimic
natur
propag
viral
infect
site
inocul
distant
target
organ
mous
model
implant
flank
tumor
provid
conveni
model
inject
tumor
superfici
human
patient
spontan
malign
tumor
often
develop
intern
viscer
organ
melanoma
head
neck
cancer
lower
gastrointestin
malign
may
better
suit
inject
due
anatom
posit
although
advanc
intervent
radiolog
use
comput
tomographi
mri
imag
guidanc
place
needl
mani
tumor
may
access
virotherapi
one
addit
advantag
inject
iv
rout
threshold
concentr
input
viru
requir
initi
spread
infect
tumor
tissu
easili
achiev
intraperiton
viru
administr
often
pursu
virotherapi
studi
aim
impact
ovarian
cancer
dissemin
intraperiton
malign
intrapleur
administr
pursu
mesothelioma
therapi
approach
similar
administr
viru
come
direct
contact
tumor
cell
inject
caviti
although
greater
risk
input
viru
immedi
neutral
antibodi
protein
ascit
pleural
fluid
intraves
instil
viru
favor
rout
administr
treatment
earlystag
bladder
cancer
requir
futur
scienc
group
wwwfuturemedicinecom
input
viru
stabl
urin
also
immedi
brain
cancer
surgeri
attempt
control
residu
diseas
viru
often
instil
directli
resect
caviti
perhap
signific
barrier
widespread
ov
deliveri
rapid
neutral
clearanc
circul
viru
particl
antibodi
complement
protein
coat
viru
block
abil
interact
cellular
receptor
acceler
fc
receptormedi
clearanc
splenic
macrophag
hepat
kupffer
cell
antibodi
neutral
shown
reduc
efficaci
system
administ
ov
measl
vsv
vaccinia
preclin
model
previou
exposur
occur
preform
antibodi
reduc
effect
initi
treatment
howev
situat
typic
far
problemat
second
subsequ
dose
even
low
seropreval
virus
first
dose
induc
power
primari
antivir
antibodi
respons
boost
preexist
respons
troublesom
respons
constrain
coadminist
immunosuppress
drug
cyclophosphamid
cyclophosphamid
administ
concurr
ov
shown
suppress
delay
develop
humor
cytotox
antivir
tcell
respons
high
seropreval
virus
one
approach
circumv
viral
neutral
preform
antibodi
engin
switch
viral
coat
protein
ov
eg
adenoviru
offer
menu
differ
serotyp
provid
basi
serotyp
switch
success
dose
therapi
avoid
antibodi
neutral
although
greatli
complic
product
develop
pathway
sinc
serotyp
consid
distinct
pharmaceut
product
monotyp
virus
measl
serotyp
switch
option
antimeasl
antibodi
circumv
substitut
surfac
glycoprotein
measl
relat
noncrossreact
morbilliviru
canin
distemp
viru
altern
immunodomin
epitop
measl
surfac
glycoprotein
modifi
mutat
key
surfac
residu
elimin
introduc
glycosyl
signal
shield
nlink
glycan
worth
note
viru
engin
strategi
potenti
alter
viral
receptor
usag
henc
tumor
cell
tropism
may
limit
util
mengoviru
vsv
newcastl
diseas
viru
exampl
anim
pathogen
develop
oncolyt
agent
appeal
oncolyt
platform
due
coupl
abil
select
propag
human
tumor
low
seropreval
human
popul
unlik
virus
measl
almost
exclus
human
cell
tropism
zoonot
virus
capabl
infect
rodent
human
tumor
cell
allow
preclin
test
inform
immunocompet
mous
cancer
model
anoth
strategi
avoid
neutral
block
reticuloendotheli
system
polyinosin
acid
clodronateload
liposom
poison
deplet
splenic
macrophag
kupffer
cell
approach
shown
slow
clearanc
circul
viru
particl
coat
antibodi
complement
virusinfect
cell
carrier
also
use
transport
virus
via
bloodstream
site
tumor
growth
part
possibl
eclips
period
cell
carrier
infect
display
viral
protein
surfac
therefor
bound
viru
neutral
antibodi
still
abl
extravas
tumor
neovessel
releas
infecti
progeni
tumor
parenchyma
sever
cell
carrierov
combin
use
includ
mesenchym
stem
cell
dendrit
cell
cell
endotheli
progenitor
cell
carrier
cell
believ
home
effici
tumor
respond
chemotact
signal
aris
hypoxia
inflamm
replic
amplif
tumor
major
featur
set
ov
apart
anticanc
drug
tradit
chemotherapi
immunotherapi
small
molecul
inhibitor
target
tumor
cell
amplifi
site
action
spread
site
tumor
growth
specif
well
speed
extent
viru
replic
key
determin
therapeut
index
efficacytox
ratio
ov
therapeut
paramet
modifi
viru
engin
addit
kinet
spread
impact
combin
viru
immunomodulatori
drug
idea
viru
select
tropism
cancer
tissu
obviou
appeal
even
natur
occur
virus
tropism
modifi
tumor
offer
favor
environ
support
product
infect
born
case
report
temporari
remiss
regress
differ
cancer
concurr
viral
infect
sever
reason
tumor
gener
suscept
normal
tissu
viru
attack
poorli
develop
lymphat
high
nonsuppress
metabol
activ
resist
apoptosi
poor
respons
interferon
intrins
suppress
immun
effector
cell
move
direct
intent
use
viru
infect
mediat
tumor
destruct
appar
target
viru
exquisit
tumor
specif
superior
non
target
counterpart
allow
administr
higher
tumor
destruct
dose
without
toxic
normal
tissu
viru
tropism
determin
mani
factor
understood
suffici
manipul
enhanc
tumor
specif
receptor
tropism
natur
occur
virus
rare
interest
tumor
target
true
tissuecultureadapt
vaccin
lineag
virus
evolv
laboratori
use
receptor
abundantli
express
cancer
cell
exampl
includ
receptor
tropism
vaccin
lineag
measl
viru
heparan
sulfat
tropism
laboratoryadapt
sindbi
viru
greater
specif
desir
may
possibl
engin
new
receptor
tropism
modifi
structur
viral
attach
protein
exampl
display
polypeptid
ligand
extrem
cterminu
measl
h
glycoprotein
howev
mani
virus
display
polypeptid
ligand
surfac
redirect
attach
confer
new
receptor
tropism
remain
area
activ
investig
addit
depend
specif
entri
receptor
surfac
glycoprotein
mani
envelop
virus
sometim
critic
viral
protein
must
proteolyt
activ
compet
mediat
viru
entri
engin
proteas
target
sequenc
viral
glycoprotein
possibl
gener
virus
whose
propag
depend
exposur
specif
proteas
high
abund
urokinas
matrix
metalloproteinas
cathepsin
beyond
step
cell
entri
virus
exquisit
sensor
intracellular
process
therefor
adapt
engin
sever
way
intracellular
target
cancer
cell
best
understood
consid
fundament
aspect
interplay
viru
infect
cell
incom
viru
aim
usurp
cellular
synthet
machineri
gener
progeni
virus
cell
resist
takeov
bid
rapidli
detect
viru
invas
trigger
signal
cascad
lead
establish
antivir
state
releas
interferon
induc
anti
viral
state
adjac
cell
antivir
state
complex
suppress
protein
translat
key
compon
apoptosi
also
trigger
viru
detect
machineri
infect
cell
die
abl
manufactur
viru
progeni
viru
success
must
combat
host
cell
respons
avoid
detect
long
possibl
suppress
establish
antivir
state
prevent
apoptosi
virtual
natur
occur
virus
therefor
encod
protein
inhibit
apop
tosi
antivir
state
remov
accessori
function
viral
genom
lead
viru
attenu
normal
tissu
much
lesser
degre
cancer
tissu
cancer
cell
intrins
resist
apoptosi
establish
antivir
state
make
highli
suscept
attenu
virus
longer
abl
control
process
provid
mechanist
basi
physiolog
target
sever
virus
vsv
mutat
matrix
gene
whose
encod
protein
block
interferon
respons
hsv
mutat
copi
gene
interfer
interferonmedi
shutoff
host
protein
synthesi
enhanc
neurovirul
adenoviru
mutat
protein
one
whose
action
inhibit
apoptot
activ
virus
engin
exclus
replic
tumor
cell
combin
viru
need
physiolog
peculiar
intrins
tumorigenesi
exampl
viral
encod
thymidin
kinas
tk
requir
hsv
vaccinia
viru
infect
increas
suppli
deoxynucleotid
triphosph
requir
synthesi
progeni
viru
genom
elimin
tk
futur
scienc
group
wwwfuturemedicinecom
gene
viral
genom
restrict
viral
replic
cancer
cell
upregul
human
tk
anoth
exampl
viru
exploit
high
replic
rate
tumor
cell
replic
compet
ctype
retroviru
encod
drug
activ
enzym
cytosin
deaminas
cd
sinc
integr
ctype
retrovirus
sphase
depend
viru
select
amplifi
rapidli
prolifer
tumor
tissu
engin
tumor
specif
also
achiev
detarget
virus
ablat
unwant
tropism
caus
target
patholog
normal
tissu
mircrorna
target
best
exampl
approach
exampl
mirna
target
use
control
tropism
oncolyt
coxsackieviru
viru
caus
rapid
tumor
regress
follow
fatal
myositi
murin
model
myeloma
melanoma
insert
musclespecif
mirna
target
viral
genom
elimin
muscl
toxic
left
antitumor
potenc
viru
intact
shown
due
mirnamedi
recognit
rapid
destruct
viral
genom
muscl
cell
mirna
target
sinc
appli
mani
ov
divers
viru
famili
provid
conveni
econom
strategi
use
sequenc
insert
base
control
unwant
viru
tropism
appropri
target
viru
infect
tumor
cell
extent
subsequ
propag
becom
key
driver
potenc
datadriven
mathemat
model
system
oncolyt
virotherapi
indic
tumor
erad
depend
two
major
paramet
initi
densiti
distribut
infecti
foci
tumor
ultim
size
infecti
center
aris
individu
infect
cell
ie
viru
spread
viral
spread
may
occur
variou
mechan
local
spread
may
occur
intercellular
fusion
direct
transfer
viru
infect
adjac
cell
releas
local
migrat
progeni
virion
interstiti
space
system
spread
free
viru
particl
virusinfect
migratori
cell
occur
via
lymphat
channel
via
bloodstream
direct
celltocel
transfer
virus
advantag
stealth
viru
neutral
antivir
antibodi
interstiti
fluid
nonfusogen
virus
arm
fusogen
membran
glycoprotein
fmg
enabl
stealthi
spread
intercellular
fusion
lead
format
larg
nonviabl
multinucl
syncytia
may
also
serv
excel
antigen
present
cell
amplif
antitumor
immun
respons
way
exampl
vsv
encod
measl
fusogen
glycoprotein
hsv
encod
fusogen
gibbon
ape
leukemia
viru
glycoprotein
shown
superior
efficaci
compar
correspond
parent
virus
case
free
viru
particl
suscept
antibodi
neutral
stroma
tumor
also
potenti
limit
diffus
block
system
releas
fibroblast
endotheli
cell
immun
cell
ecm
make
tumor
stroma
exact
composit
vari
wide
depend
tumor
type
ecm
collagen
matrix
protein
fibril
adhes
protein
proteoglycan
creat
web
pore
size
similar
slightli
smaller
virion
destruct
ecm
compon
facilit
viral
spread
throughout
tumor
achiev
use
convent
chemoradiotherapi
deliv
matrixdegrad
enzym
collagenas
hyaluronidas
altern
approach
encod
matrixdegrad
enzym
induc
matrixdegrad
enzym
viral
genom
exampl
hyaluronidas
relaxin
encod
oncolyt
adenovirus
shown
spread
effici
experiment
tumor
anoth
factor
significantli
impact
kinet
viru
spread
burst
size
number
progeni
virus
releas
product
infect
cell
vari
wide
viral
famili
picornavirus
vsv
vaccinia
viru
releas
progeni
singl
infect
cell
delay
h
addit
innat
antivir
immun
adapt
cellmedi
immun
respons
typic
requir
complet
elimin
viral
infect
act
elimin
infect
cell
progeni
releas
oncolyt
virotherapi
therefor
view
race
spread
viru
respond
immun
system
reason
faster
move
viral
infect
often
consid
capabl
inflict
greater
damag
infect
tumor
contain
immun
system
howev
defens
virus
smaller
burst
size
releas
progeni
bud
tend
less
review
maroun
ammayappan
schulz
peng
russel
futur
scienc
group
rapidli
control
innat
adapt
host
immun
respons
therefor
classic
race
hare
tortois
difficult
predict
whether
fast
slow
replic
viru
show
superior
efficaci
given
preclin
cancer
model
matter
extens
ov
infect
spread
tumor
sizabl
percentag
cancer
cell
escap
infect
kill
uninfect
bystand
cancer
cell
therefor
critic
oncolyt
virotherapi
becom
cur
oppos
tumor
debulk
strategi
bystand
kill
achiev
local
site
spread
infect
system
uninfect
tumor
site
genet
arm
viru
use
one
sever
possibl
approach
exampl
ov
engin
encod
secret
protein
select
mediat
destruct
neighbor
andor
distant
cancer
cell
altern
arm
suicid
gene
prodrug
convertas
whose
encod
protein
convert
harmless
prodrug
diffus
anticanc
drug
third
approach
ov
arm
radioconcentr
gene
infect
tumor
cell
abl
concentr
radioisotop
whose
emit
electron
damag
adjac
uninfect
tumor
cell
fourth
engin
fuse
infect
tumor
cell
uninfect
neighbor
cell
last
mean
least
engin
express
one
gene
capabl
amplifi
immunemedi
kill
uninfect
tumor
cell
approach
discuss
use
specif
exampl
illustr
concept
gener
rule
viru
arm
gene
encod
secret
toxin
toxin
target
kill
cancer
cell
absenc
target
would
littl
prospect
avoid
offtarget
toxic
immunotoxin
bifunct
protein
plant
bacteri
toxin
typic
ribosom
inhibitor
fuse
singl
chain
antibodi
polypeptid
domain
target
endocytosi
cancer
cell
theori
molecul
extens
investig
advanc
human
clinic
trial
particularli
treatment
bcell
tcell
malign
could
express
engin
ov
genom
unlik
secret
toxin
prodrug
convertas
pose
risk
increas
ov
virul
toxic
potenti
manifest
presenc
exogen
ad
prodrug
reason
approach
extens
studi
perhap
wellknown
convertaseprodrug
combin
hsv
tk
use
ganciclovir
tk
convert
ganciclovir
ganciclovir
monophosph
process
intracellularli
ganciclovir
triphosph
dna
synthesi
chain
termin
kill
divid
cell
enter
phase
major
weak
tkganciclovir
system
asid
inabl
kill
nondivid
tumor
cell
limit
bystand
kill
potenti
ganciclovir
monophosph
releas
cell
gener
impact
uninfect
tumor
cell
unless
connect
infect
cell
via
gap
junction
pass
encod
connexin
gap
junction
protein
ov
genom
enhanc
bystand
kill
effect
tk
attent
shift
convertas
notabl
cd
cd
convert
inert
small
molecul
administ
intraven
antimetabolit
irrevers
inhibit
thymidyl
synthas
approv
chemotherapeut
agent
varieti
cancer
anal
breast
colorect
esophag
stomach
pancreat
skin
argument
support
system
local
product
ovinfect
tumor
creat
concentr
gradient
expos
tumor
cell
higher
concentr
drug
compar
distant
tissu
therebi
amelior
toxic
enhanc
therapeut
index
drug
howev
freeli
diffus
local
product
drug
cdposit
tumor
expos
high
concentr
lead
system
toxic
dose
must
therefor
adjust
accordingli
cd
incorpor
sever
ov
includ
adenovirus
paramyxovirus
poxvirus
one
advanc
ahead
other
clinic
test
ctype
retroviru
current
evalu
phase
iii
clinic
trial
treatment
patient
malign
glioma
besid
tk
cd
prodrug
convertas
system
report
ov
engin
express
cyclophosphamideactiv
protein
futur
scienc
group
wwwfuturemedicinecom
secret
human
intestin
carboxylesteras
shice
fludarabin
phosphat
activ
purin
nucleotid
phosphorylas
iodid
critic
compon
thyroxin
concentr
thyroid
follicular
cell
thyroid
sodium
iodin
symport
ni
cell
surfac
glycoprotein
transmembran
domain
radioiodin
therefor
use
routin
clinic
thyroid
imag
ablat
overact
thyroid
tissu
includ
metastat
thyroid
cancer
facilit
readi
avail
sever
iodin
radioisotop
notabl
ifor
camera
singlephoton
emiss
comput
tomographi
imag
pet
imag
isotop
thyroid
ablat
besid
radioiodin
ni
concentr
sever
relat
anion
equal
greater
valu
singlephoton
emiss
comput
tomographi
tco
pertechnet
pet
b
f
tetrafluorobor
tissu
ablat
astatid
reo
perrhen
emiss
ihav
averag
path
length
approxim
mm
tissu
therefor
inflict
signific
damag
cell
adjac
load
ni
express
cell
reo
emiss
path
length
longer
ni
neg
tumor
cell
even
like
damag
particl
crossfir
radioisotop
use
unsurprisingli
therefor
ni
gene
engin
sever
ov
whose
spread
elegantli
map
monitor
tumorbear
mice
serial
radiotrac
imag
whose
potenc
substanti
boost
appropri
time
administr
least
two
nisexpress
ov
prostatetarget
oncolyt
adenoviru
measl
viru
advanc
human
clinic
trial
posit
imag
data
report
fusion
lipid
envelop
incom
viru
limit
membran
target
cell
necessari
step
life
cycl
envelop
viru
deliv
encapsid
viral
genom
target
cell
cytoplasm
virustocel
fusion
reaction
mediat
fmg
embed
envelop
viru
may
occur
cell
surfac
neutral
ph
endosom
compart
acid
ph
neutral
ph
fusion
trigger
receptor
attach
cell
express
certain
viral
encod
neutral
phactiv
fmg
surfac
may
fuse
neighbor
receptor
posit
cell
celltocel
fusion
give
rise
multinucl
syncytia
hallmark
cytopath
signatur
fusogen
viru
eg
measl
often
fmg
activ
incorpor
bud
viru
particl
caus
celltocel
fusion
must
modifi
exampl
cytoplasm
tail
truncat
render
constitut
fusogen
either
way
fmgdriven
fusion
ovinfect
cell
uninfect
neighbor
cell
lead
increas
bystand
kill
multinucl
syncytia
nonviabl
well
highli
immunogen
base
observ
nonfusogen
ov
arm
fmg
therebi
confer
superior
oncolyt
potenc
one
exampl
oncolyt
herp
viru
render
highli
fusogen
engin
encod
cytoplasm
truncat
gibbon
ape
leukemia
viru
envelop
glycoprotein
anoth
studi
oncolyt
vsv
render
highli
fusogen
replac
surfac
glycoprotein
g
hemagglutinin
fusion
glycoprotein
measl
viru
tumor
cell
intrins
immunogen
mutat
burden
driver
mutat
disrupt
abil
respond
normal
growth
regulatori
signal
wherea
passeng
mutat
occur
random
throughout
genom
uniqu
given
tumor
mutat
chang
code
sequenc
express
protein
result
gener
nonselfpeptid
present
cell
surfac
neoantigen
mhcpeptid
complex
neoepitop
order
avoid
immun
detect
destruct
cancer
must
therefor
evad
immun
system
effect
thu
tumor
lack
lymphat
channel
sustain
high
interstiti
pressur
imped
leucocyt
extravas
releas
immunosuppress
substanc
prostaglandin
reprogram
macrophag
phenotyp
destroy
abil
process
present
tumor
antigen
may
even
lose
abil
present
mhcpeptid
complex
tumor
cell
surfac
mani
tumor
review
maroun
ammayappan
schulz
peng
russel
futur
scienc
group
cell
also
overexpress
receptor
surfac
last
line
defens
attack
lymphocyt
checkpoint
receptor
interact
surfac
approach
cell
lead
tcell
anergi
checkpoint
inhibitor
anti
bodi
current
transform
field
immunooncolog
block
andor
interact
therebi
unveil
cancer
render
suscept
tcellmedi
kill
abil
amplifi
immunemedi
kill
uninfect
tumor
cell
ov
may
ideal
partner
checkpoint
inhibitor
antibodi
therapi
engin
variou
way
maxim
immun
enhanc
properti
immedi
follow
ov
infect
tumor
cell
releas
type
interferon
drive
innat
inflammatori
immun
respons
subsequ
undergo
necrosi
releas
tumor
antigen
interstiti
space
phagocytos
inflammatori
effector
cell
transport
region
lymph
node
crosspresent
helper
effector
cell
prolifer
reenter
bloodstream
traffic
back
tumor
extravas
tumor
neovessel
engag
neoantigen
mhcpeptid
complex
uninfect
tumor
cell
kill
step
process
impact
viru
engin
kinet
mode
cell
kill
manipul
see
previou
section
viru
spread
also
ov
arm
wide
varieti
immunoregulatori
gene
whose
product
secret
interstiti
fluid
space
thu
ov
engin
express
follow
high
level
type
interferon
better
drive
earli
innateinflammatori
respons
gmcsf
stimul
phagocyt
activ
lymph
node
traffick
profession
antigen
present
cell
chemokin
enhanc
recruit
immun
inflammatori
effector
cell
especi
cytotox
cell
cytokin
drive
activ
prolifer
tumorresid
cytotox
cell
bispecif
tcell
engag
enabl
tumor
cell
kill
cell
recogn
tumor
antigen
checkpoint
inhibitor
antibodi
block
protect
shield
protect
tumor
cell
tcell
attack
cytokin
increas
mhcpeptid
neoantigen
express
uninfect
tumor
cell
clone
tumor
antigen
amplifi
tumorspecif
immun
approach
proven
benefici
select
preclin
anim
model
immun
destruct
tumor
domin
ov
effect
equal
like
decreas
potenc
speed
viru
elimin
situat
spread
viru
domin
engin
virus
increas
stealth
greater
specif
faster
spread
enhanc
potenc
without
risk
ov
gain
new
properti
check
balanc
must
appli
assur
readili
evolv
pathogen
let
alon
transmiss
pathogen
could
pose
risk
immedi
contact
treat
patient
also
greater
popul
far
ov
except
safeti
record
clinic
seriou
advers
event
minim
mortal
report
human
trial
howev
sinc
efficaci
also
limit
remain
possibl
toxic
profil
may
appear
less
favor
dose
increas
newer
ov
virusdrug
combin
advanc
clinic
test
current
activ
clinic
trial
ongo
use
ov
alon
combin
therapi
number
patient
particip
trial
grow
insight
rare
advers
effect
common
advers
effect
report
recent
ov
trial
fever
flulik
symptom
howev
potenti
sever
advers
reaction
much
clearli
demonstr
earliest
virotherapi
trial
undertaken
death
sever
advers
reaction
infrequ
record
due
presum
ov
replic
normal
tissu
notabl
brain
especi
immunocompromis
cancer
patient
viral
cytotox
basi
tumor
cell
death
necessari
oncolyt
activ
offtarget
infect
kill
normal
cell
poorli
target
ov
ov
evolv
new
tropism
treat
patient
caus
unwant
normal
tissu
patholog
ov
therefor
delic
balanc
retain
enough
virul
substanti
decreas
tumor
burden
versu
suffici
target
attenu
caus
new
diseas
patient
cancerspecif
target
critic
safeti
featur
virus
evolv
viral
popul
dynam
evolut
constant
accompani
spread
viru
infect
whether
viru
oncolyt
vivo
progeni
therapeut
ov
differ
averag
singl
point
mutat
per
genom
input
viru
henc
input
viru
amplifi
gener
swarm
quasispeci
virus
one
slightli
imperfect
replica
input
viru
swarm
progeni
virus
subject
select
pressur
encount
new
biolog
nich
treat
cancer
patient
thu
happen
member
swarm
capabl
infect
normal
host
tissu
viru
may
gain
new
foothold
evolv
gain
new
cell
tropism
lose
restrict
factor
therefor
signific
theoret
concern
oncolyt
infect
yet
document
human
trial
preclin
model
howev
given
import
particular
scenario
great
deal
attent
paid
problem
investig
also
regulatori
agenc
understand
select
pressur
oper
within
tumor
host
well
role
viral
quasispeci
treatment
outcom
activ
area
research
rna
dna
virus
exist
popul
quasispeci
collect
relat
viral
genom
undergo
variat
select
pressur
gener
quasispeci
occur
viral
genom
copi
replic
cycl
viral
polymeras
typic
error
rate
introduc
averag
one
base
mutat
per
progeni
genom
gener
larger
viru
genom
lower
polymeras
error
rate
picornavirus
among
smallest
virus
develop
oncolyt
therapi
posit
sens
rna
genom
rang
kb
length
rna
polymeras
correspondingli
high
intrins
error
rate
product
viru
clinic
applic
highli
regul
process
involv
multipl
round
replic
achiev
enough
viru
patient
viral
product
therefor
alreadi
swarm
quasispeci
time
administ
patient
mutat
undergo
addit
round
replic
vivo
studi
mutat
rate
viral
polymeras
gener
quasi
speci
evolut
viral
popul
evolut
domin
subspeci
within
viru
popul
therefor
great
interest
relev
ov
field
although
interest
determin
whether
ov
encod
modifi
polymeras
higher
fidel
exhibit
improv
safeti
profil
note
ov
revers
pathogen
state
yet
observ
clinic
also
true
mani
timehonor
viral
vaccin
exampl
year
widespread
measl
vaccin
use
attenu
edmonston
lineag
substrain
never
document
revers
back
wildtyp
phenotyp
even
iv
dose
high
tcid
administ
immunosuppress
measl
antibodi
neg
myeloma
patient
oncolyt
virotherapi
studi
polymeras
infidel
sole
driver
viru
genom
diversif
evolut
mani
virus
recombin
homolog
viral
genom
occur
two
relat
virus
infect
cell
type
recombin
featur
neg
strand
rna
viru
evolut
nascent
progeni
viral
genom
cotranscript
incorpor
helic
ribonucleocapsid
structur
prevent
recombin
howev
posit
sens
rna
picornavirus
dna
virus
adenoviru
hsv
vaccinia
import
consid
possibl
input
viru
may
encount
recombin
homolog
wildtyp
viru
treat
patient
recombin
never
document
ov
trial
well
describ
exampl
field
vaccinolog
reemerg
pathogen
poliovirus
recombin
vaccin
genom
natur
circul
picornaviru
genom
view
risk
gener
consid
inadvis
arm
virus
therapeut
transgen
theoret
potenti
increas
pathogen
transfer
relat
natur
circul
viru
gene
encod
immunosuppress
antiapoptot
directli
cytotox
protein
list
certain
virus
segment
genom
notabl
orthomyxovirus
eg
influenza
capabl
rapid
evolut
genom
fragment
reassort
multipl
infect
cell
reassort
genom
fragment
virusinfect
bird
pig
consid
key
driver
antigen
shift
occur
evolut
new
pathogen
influenza
viru
strain
import
safeti
concern
may
explain
oncolyt
influenza
virus
yet
advanc
human
clinic
trial
toxic
risk
associ
prolif
evolutionari
capac
ov
consider
interest
conting
plan
termin
spread
andor
transmiss
ov
infect
reliabl
antivir
medic
avail
tkexpress
herp
virus
case
major
virus
develop
ov
platform
attent
therefor
direct
develop
safeti
switch
engin
ov
genom
trigger
demand
termin
vivo
replic
two
socal
suicid
gene
tk
induc
caspas
interest
regard
gene
use
safeti
switch
elimin
genet
modifi
cell
caus
graft
versu
host
diseas
human
clinic
trial
virus
engin
encod
tk
also
control
ganciclovir
therapi
consid
reliabl
safeti
switch
everpres
risk
emerg
viral
quasispeci
tk
inactiv
mutat
develop
univers
highli
reliabl
safeti
switch
remain
one
signific
research
challeng
face
field
oncolyt
virotherapi
limit
pathogen
potenti
ov
also
accomplish
enhanc
host
innat
immun
respons
vsv
engin
express
induc
antivir
state
reduc
prolifer
cell
cell
capabl
respond
interferon
signal
limit
viral
replic
respons
viral
produc
interferon
restrict
viral
replic
tumor
defect
innat
respons
express
infect
tumor
cell
also
prevent
offtarget
infect
nearbi
tissu
paracrin
signal
anoth
way
achiev
similar
effect
mutat
vsv
matrix
protein
respons
limit
cellular
product
type
interferon
similar
approach
inactiv
viral
gene
combat
innat
immun
extens
util
ov
field
across
broad
rang
viral
famili
sensit
ov
innat
immun
respons
limit
offtarget
infect
enhanc
tumorspecif
tropism
increas
therapeut
index
obviou
reason
ov
transmiss
treat
patient
caregiv
famili
member
cowork
pet
speci
highli
undesir
infecti
viru
particl
may
present
blood
treat
patient
may
shed
environ
urin
fece
saliva
bodili
secret
contact
bodi
fluid
ovtreat
patient
therefor
may
potenti
spread
infect
new
host
risk
ov
transmiss
typic
unknown
firstinhuman
phase
trial
initi
usual
implement
standard
infect
contain
measur
throughout
studi
care
monitor
bodi
fluid
appear
disappear
viral
genom
infecti
viru
progeni
certain
virus
contain
may
consid
unnecessari
particularli
alreadi
widespread
popul
immun
ov
question
eg
measl
extens
human
experi
exposur
relat
viru
form
live
viral
vaccin
eg
vaccinia
conting
plan
may
also
requir
call
quarantin
ovtreat
patient
treatment
toxic
associ
longer
period
shed
realiti
date
instanc
transmiss
ov
patient
caregiv
contact
demonstr
exampl
longterm
viru
persist
shed
treat
patient
light
inconveni
undesir
ov
shed
interest
engin
strategi
may
select
interfer
process
one
exampl
wildtyp
measl
viru
highli
transmiss
airborn
viru
use
receptor
enter
airway
epitheli
cell
whenc
progeni
shed
respiratori
secret
elimin
tropism
strateg
mutat
key
surfac
residu
hemagglutinin
attach
protein
result
viru
still
caus
measl
nonhuman
primat
longer
shed
respiratori
secret
urin
measl
viru
rna
infecti
viru
detect
blood
urin
saliva
myeloma
patient
week
iv
administr
oncolyt
measl
viru
especi
higher
dose
level
possibl
shed
might
elimin
use
blind
version
viru
viru
shed
also
detect
human
clinic
trial
hsv
reoviru
vaccinia
reoviru
adenoviru
oncolyt
less
readili
detect
follow
therapi
oncolyt
vsv
poliovirus
howev
futur
scienc
group
wwwfuturemedicinecom
note
genom
sequenc
detect
shed
materi
infecti
viru
particl
recov
ovtreat
patient
preexist
antivir
immun
formid
barrier
efficaci
particularli
viru
administ
intraven
howev
preexist
antivir
immun
caregiv
patient
contact
provid
reassur
protect
viru
transmiss
convers
particular
efficaci
barrier
circumv
use
ov
engin
antibodi
evas
select
low
seropreval
risk
epidem
spread
human
popul
uncheck
preexist
herd
immun
loom
larger
altern
strategi
often
use
side
step
antibodi
neutral
least
first
dose
viru
administ
use
ov
deriv
zoonot
anim
virus
new
castl
diseas
viru
chicken
vsv
cattl
myxomaviru
rabbit
seneca
valley
viru
pig
mengoviru
eg
mous
monkey
addit
regulatori
execut
summari
virus
anticanc
drug
virus
natur
possess
mani
properti
favor
infect
cancer
cell
enhanc
natur
properti
ad
new
properti
direct
evolut
genet
engin
use
creat
oncolyt
virus
ov
emerg
new
anticanc
drug
class
ov
target
tumor
tissu
kill
tumor
cell
directli
amplifi
antitumor
immun
must
safe
patient
healthcar
worker
divers
viru
famili
engin
techniqu
allow
creation
ov
wide
rang
properti
tailor
type
cancer
ov
obey
convent
pharmacolog
principl
due
abil
biolog
amplifi
administr
intraven
deliveri
allow
viru
reach
distant
site
metastasi
via
circul
extravas
tumor
parenchyma
ineffici
intratumor
inject
concentr
viru
site
tumor
growth
regress
distant
tumor
requir
viru
spread
system
induc
system
antitumor
immun
respons
neutral
antibodi
hepatosplen
sequestr
viru
macrophag
dilut
viru
blood
tissu
may
limit
effect
treatment
target
viral
spread
tumor
cell
accomplish
transduct
target
modifi
receptor
tropism
transcript
target
control
viru
gene
express
tumorspecif
promot
physiolog
target
disrupt
viral
immun
combat
protein
apoptosi
target
disrupt
viral
antiapoptot
protein
mirna
target
viral
replic
tumor
subsequ
spread
infect
uninfect
cell
critic
tumor
erad
addit
transgen
allow
tumor
cell
escap
viral
infect
kill
bystand
effect
better
target
immun
system
secret
toxin
prodrug
convertas
immunostimulatori
protein
incorpor
ov
increas
treatment
efficaci
care
step
must
taken
avoid
creation
ov
might
evolv
becom
seriou
pathogen
conting
plan
termin
spread
andor
transmiss
infect
increas
clinic
confid
viral
therapi
ideal
ov
nontransmiss
scrutini
gener
requir
virus
eg
us
depart
agricultur
address
addit
risk
environment
releas
epidem
spread
domest
anim
particularli
relat
agricultur
livestock
virus
last
har
benefit
cancer
patient
ov
field
move
well
beyond
proof
principl
human
studi
viru
engin
key
continu
advanc
come
year
virtual
everi
compon
everi
natur
occur
laboratoryadapt
viru
engin
andor
evolv
enhanc
suitabl
cancer
therapi
current
wit
unstopp
creativ
activ
area
safeti
obvious
paramount
import
rel
new
field
therefor
close
regul
design
stage
clinic
implement
consid
current
trajectori
ov
research
littl
doubt
virus
way
becom
one
foundat
modal
futur
cancer
treatment
regimen
stephen
russel
